GSK asks European regulator to OK malaria shot

July 24, 2014

(AP)—Pharma giant GSK said Thursday it is submitting its malaria vaccine for regulatory approval to the European Medicines Agency.

The experimental shot is the most advanced candidate vaccine for malaria but results from previous trials have been disappointing. Research published in 2012 showed the shot only reduced malaria cases by about 30 percent in babies aged six to 12 weeks, the target age for immunization. The vaccine, known as RTS,S, seems to work better in older children but its efficacy faded over time.

In a statement on Thursday, GSK said its vaccine is aimed only for use against the malaria parasite most prevalent in Africa.

There is currently no licensed vaccine for malaria. The is spread by mosquitoes and kills about 650,000 people every year, mostly in Africa.

Explore further: Malaria vaccine candidate reduces disease over 18 months of follow-up in phase 3 children's study

Related Stories

GSK to seek green light for malaria vaccine

October 8, 2013

British drug maker GlaxoSmithKline (GSK) said on Tuesday it hoped to get the green light for a prototype vaccine against malaria after trials showed it offered children a partial shield against the disease.

Recommended for you

Gut environment could reduce severity of malaria

February 8, 2016

Microorganisms in the gut could play a role in reducing the severity of malaria, according to a new study co-authored by researchers at the University of Tennessee, Knoxville, and the University of Louisville.

Easier diagnosis for fungal infection of the lungs

January 18, 2016

A new clinical imaging method developed in collaboration with a University of Exeter academic may enable doctors to tackle one of the main killers of patients with weakened immune systems sooner and more effectively.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.